PeptideScanner retained ClinicalTrials.gov record NCT01067521 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT02225366 at 2026-11-16T16:10:17.145Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was ll-37.
PeptideScanner retained ClinicalTrials.gov record NCT02499900 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT02693119 at 2026-07-30T19:56:31.565Z. Its registry update date was 2021-11-30, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT01836068 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-23, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT03357380 at 2026-07-30T19:56:31.568Z. Its registry update date was 2021-11-22, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01751451 at 2026-11-15T21:52:09.579Z. Its registry update date was 2021-11-19, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT00516386 at 2026-11-16T17:35:13.282Z. Its registry update date was 2021-11-18, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT04846218 at 2026-11-15T21:49:16.513Z. Its registry update date was 2021-11-18, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT02215070 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-11-17, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00176592 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT02595749 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-11-15, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT02489357 at 2026-11-15T21:52:09.579Z. Its registry update date was 2021-11-12, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT03611582 at 2026-07-30T19:56:31.576Z. Its registry update date was 2021-11-11, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00537394 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-04, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00001118 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00031044 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00051831 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-11-01, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT04943159 at 2026-07-30T19:57:27.404Z. Its registry update date was 2021-10-26, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT05086614 at 2026-11-15T22:10:40.222Z. Its registry update date was 2021-10-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT03998163 at 2026-11-15T21:56:33.343Z. Its registry update date was 2021-10-15, and PeptideScanner's reviewed identity mapping was difelikefalin.
PeptideScanner retained ClinicalTrials.gov record NCT03710889 at 2026-07-30T19:57:27.406Z. Its registry update date was 2021-10-15, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00979745 at 2026-07-30T19:57:27.405Z. Its registry update date was 2021-10-12, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03096847 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-10-11, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT02889393 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-10-06, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04425746 at 2026-07-30T19:57:27.405Z. Its registry update date was 2021-10-01, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03103009 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-29, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT03716115 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-09-27, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00171730 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-09-05, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT03625778 at 2026-11-16T01:47:38.899Z. Its registry update date was 2021-08-23, and PeptideScanner's reviewed identity mapping was cotadutide.
PeptideScanner retained ClinicalTrials.gov record NCT03734627 at 2026-07-30T19:59:58.328Z. Its registry update date was 2021-08-16, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT03588611 at 2026-11-15T21:58:19.888Z. Its registry update date was 2021-08-09, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT04318743 at 2026-11-16T01:46:56.290Z. Its registry update date was 2021-07-14, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03107091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2021-07-13, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT03667053 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02023411 at 2026-07-30T20:02:09.392Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00003653 at 2026-07-30T20:02:09.393Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01590433 at 2026-07-30T20:02:09.394Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00438906 at 2026-11-16T01:34:15.953Z. Its registry update date was 2021-06-18, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT00912093 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT00930644 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00997204 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT02518191 at 2026-11-15T21:50:32.222Z. Its registry update date was 2021-06-11, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT01560403 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00081458 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00097695 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT00500656 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT01952080 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02340819 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01386658 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT01919801 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-08, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT01209351 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-04, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00798967 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02045264 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT03888755 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-03, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT00171951 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT00172185 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00072839 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-25, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03688711 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-19, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT00308438 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00819468 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04347252 at 2026-07-30T20:03:05.484Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT03929367 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-05-13, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT01522417 at 2026-11-15T21:59:29.646Z. Its registry update date was 2021-05-13, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT00344760 at 2026-11-16T01:41:15.051Z. Its registry update date was 2021-05-11, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT03571516 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-11, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02685852 at 2026-07-30T20:03:05.483Z. Its registry update date was 2021-05-06, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03216226 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-04, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT01292252 at 2026-07-30T20:03:05.485Z. Its registry update date was 2021-05-03, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT03299244 at 2026-11-15T22:07:29.454Z. Its registry update date was 2021-04-30, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT03935399 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-04-05, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT02473406 at 2026-11-15T22:10:40.222Z. Its registry update date was 2021-04-05, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT01468532 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-03-25, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT03735225 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02616003 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00937157 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-03-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT04704713 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-19, and PeptideScanner's reviewed identity mapping was afamelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT01338987 at 2026-07-30T20:05:17.853Z. Its registry update date was 2021-03-18, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03325816 at 2026-11-16T01:36:36.861Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
PeptideScanner retained ClinicalTrials.gov record NCT03466021 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03506841 at 2026-11-16T17:33:14.861Z. Its registry update date was 2021-03-15, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT01976728 at 2026-11-16T17:31:07.936Z. Its registry update date was 2021-03-03, and PeptideScanner's reviewed identity mapping was gonadorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00104741 at 2026-11-15T21:49:16.513Z. Its registry update date was 2021-02-21, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01270321 at 2026-11-15T22:05:38.400Z. Its registry update date was 2021-02-17, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT04751136 at 2026-11-16T17:33:14.861Z. Its registry update date was 2021-02-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT04449692 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02176382 at 2026-07-30T20:06:10.499Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00467272 at 2026-11-15T22:01:45.056Z. Its registry update date was 2021-02-08, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02055157 at 2026-07-30T20:07:13.490Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT03012594 at 2026-07-30T20:07:13.495Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT04206618 at 2026-07-30T20:07:13.493Z. Its registry update date was 2021-01-12, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02588833 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-11, and PeptideScanner's reviewed identity mapping was pegcetacoplan.
PeptideScanner retained ClinicalTrials.gov record NCT00779103 at 2026-11-16T01:35:22.086Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was histrelin.
PeptideScanner retained ClinicalTrials.gov record NCT02264639 at 2026-11-16T01:37:14.654Z. Its registry update date was 2021-01-08, and PeptideScanner's reviewed identity mapping was pegcetacoplan.